{"count":10,"next":null,"previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/ae8c5c84-c5f0-40fa-ad6f-02b549499069/","filing_uuid":"ae8c5c84-c5f0-40fa-ad6f-02b549499069","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/ae8c5c84-c5f0-40fa-ad6f-02b549499069/print/","filing_document_content_type":"text/html","income":null,"expenses":"190000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-04-16T12:48:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2026 and FY 2027 appropriations legislation, including advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, beneficiary protections, and the CY 2027 Advance Notice.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/ae8c5c84-c5f0-40fa-ad6f-02b549499069/","filing_uuid":"ae8c5c84-c5f0-40fa-ad6f-02b549499069","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/ae8c5c84-c5f0-40fa-ad6f-02b549499069/print/","filing_document_content_type":"text/html","income":null,"expenses":"190000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-04-16T12:48:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2026 and FY 2027 appropriations legislation, including advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, beneficiary protections, and the CY 2027 Advance Notice.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/673d4471-decf-4b13-aecd-f56014c37377/","filing_uuid":"673d4471-decf-4b13-aecd-f56014c37377","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/673d4471-decf-4b13-aecd-f56014c37377/print/","filing_document_content_type":"text/html","income":null,"expenses":"490000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Robert Egge","dt_posted":"2026-04-20T15:47:03-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"655 15th Street, NW","registrant_address_2":"Suite 500","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":1262,"url":"https://lda.gov/api/v1/registrants/1262/","house_registrant_id":30526,"name":"ALZHEIMER'S ASSOCIATION","description":null,"address_1":"655 15th Street, NW","address_2":"Suite 500","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ROBERT EGGE","contact_telephone":"+1 202-638-8660","dt_updated":"2026-07-30T10:03:36.870640-04:00"},"client":{"id":102599,"url":"https://lda.gov/api/v1/clients/102599/","client_id":12,"name":"ALZHEIMER'S ASSOCIATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-10"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"NAPA Reauthorization Act (P.L. 118-92) Alzheimers Accountability and Investment Act (P.L. 118-93) Comprehensive Care for Alzheimers Act (S. 626 / H.R. 1637 118th Congress) Reauthorization of the BOLD Infrastructure for Alzheimer's Act (P.L. 115-406) BOLD Reauthorization Act (P.L. 118-142) Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act (H.R. 3747 / S. 4036) The Senator Elizabeth Dole 21st Century Veterans Healthcare and Benefits Improvement Act (P.L. 118-210) VA Clinician Appreciation, Recruitment, Education, Expansion, and Retention Support (CAREERS) Act of 2023 (S. 10 118th Congress) Access to Innovative Treatments Act of 2023 (H.R. 2408 118th Congress) Mandating Exclusive Review of Individual Treatments (MERIT) Act of 2023 (H.R. 133 118th Congress) Elder Justice Reauthorization and Modernization Act of 2023 (S. 1198/H.R. 2718 118th Congress) Expanding Veterans Options for Long-Term Care Act (S. 495/H.R.1815 118th Congress) Palliative Care and Hospice Education and Training Act (S. 2287/H.R. 4425 119th Congress) Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2023 (S. 1544/H.R. 1199 118th Congress) Supporting Our Seniors Act (S. 2584 118th Congress) Alleviating Barriers for Caregiving Act (S. 3109 118th Congress) Credit for Caring Act of 2025 (S. 925/H.R. 2036) Lifespan Respite Care Reauthorization Act (S.830/H.R.2560) DeOndra Dixon Investigation of Co-occurring Conditions across the Lifespan to Understand Down Syndrome (INCLUDE) Project Act of 2025 (H.R. 3491/S. 1838) Paid Family and Medical Leave Tax Credit Extension and Enhancement Act (S. 400/H.R. 996) Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2025 (S. 2016/H.R. 4189 118th Congress; S. 1261/H.R. 4206 119th Congress) PACE Part D Choice Act (S. 1703/H.R. 3549 118th Congress) Improving Seniors' Timely Access to Care Act of 2025 (S. 1816/H.R. 3514 119th Congress) Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research and Innovation in Neurological Science (HEALTHY BRAINS) Act of 2026 (H.R. 7779 119th Congress) Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act of 2023(S. 526/H.R. 1092) Essential Caregivers Act (H.R. 6766 119th Congress) Ensuring Patient Access to Critical Breakthrough Products Act (S. 1717/H.R. 5343 119th Congress) The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act (S.2761/H.R.5269) Linking Seniors to Needed Legal Services Act (H.R. 8588, 118th Congress) Amending the Rules of the House of Representatives to establish a Permanent Select Committee on Aging (H. Res. 1029) Catching Up Family Caregivers Act (S. 5149 / H.R. 9764, 118th Congress) Improving Retirement Security for Family Caregivers Act (S. 5148 / H.R. 9765, 118th Congress) Charitable Act (S. 317/H.R. 801) Alzheimers Law Enforcement Education Act of 2025 (H.R. 3389) Health Tech Investment Act (S.1399) One Big Beautiful Bill Act (H.R. 1) Older Americans Act Reauthorization Act of 2025 (S. 2120) Lowering Costs for Caregivers Act of 2025 (S. 1565 / H.R. 138) Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act (S. 2761 / H.R. 5269) Alzheimers Screening and Prevention Act (H.R. 6130/S. 3267) Other matters related to disaster preparedness and older adults, public health emergencies, public health preparedness and response, telehealth, health disparities, and older Americans/people with disabilities in all phases of emergencies Other matters related to Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Other matters related to care payment models, including the GUIDE model Other matters related to Medicare care planning code 99483 Other matters related to health care workforce shortages Other matters related to home- and community-based services Other matters related to disaster preparedness and older adults Other matters related to Social Security Other matters related to technology-enabled collaborative learning and capacity-building models (Project ECHO) Other matters related to beta-amyloid PET scans Other matters related to selected diagnoses and services rendered under ICD-10 Other matters related to caregiving Other matters related to medical devices Other matters related to rural health Other matters related to veterans' health and traumatic brain injury (TBI) Other matters related to Tricare Other matters related to research Other matters related to biomarkers including blood based tests and cerebral spinal fluid (CSF) Other matters related to public health Other matters related to elder justice, abuse and neglect Other matters related to Medicaid Other matters related to nonprofit infrastructure and operations Other matters related to the National Plan to Address Alzheimer's Disease and the NAPA Advisory Council Other matters related to the Alzheimer's Screening and Prevention (ASAP) Act Other matters related to brain health, risk reduction, and the U.S. POINTER study and results Other matters related to biomarker disclosure and discrimination (Office of Civil Rights at HHS) Other matters related to long-term care","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55648,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"CONANT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67551,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"POLLACK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140279,"prefix":"ms","prefix_display":"MS.","first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":114396,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"HEATH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141524,"prefix":"mrs","prefix_display":"MRS.","first_name":"MARY","nickname":null,"middle_name":"AGNES","last_name":"GERMILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"OSUNA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145183,"prefix":null,"prefix_display":null,"first_name":"ZOE","nickname":null,"middle_name":null,"last_name":"SALZBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152388,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"WING","last_name":"HARPER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":56,"name":"Federal Emergency Management Agency (FEMA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":5,"name":"Government Accountability Office (GAO)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":138,"name":"Indian Health Service"},{"id":37,"name":"Justice, Dept of (DOJ)"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":91,"name":"Social Security Administration (SSA)"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Matters related to Fiscal Years 2026 and 2027 appropriations for Alzheimers funding at the National Institutes of Health, Centers for Disease Control and Prevention, Food and Drug Administration, Health Resources and Services Administration, Administration for Community Living, Department of Defense, and Indian Health Service Matters related to Fiscal Year 2026 and 2027 appropriations language reflecting scientific advances in Alzheimers at the Food and Drug Administration and the Centers for Medicare & Medicaid Services Appropriations related to OAA Title III-C Nutrition Program and appropriations related to [88 FR 80085] Initiative on Women's Health Research Other matters related to Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease Other matters related to beta-amyloid PET scans Other matters related to diagnostics for Alzheimers disease and other dementia Other matters related to brain health and risk reduction Other matters related to clinical trials","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55648,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"CONANT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140279,"prefix":"ms","prefix_display":"MS.","first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67551,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"POLLACK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141524,"prefix":"mrs","prefix_display":"MRS.","first_name":"MARY","nickname":null,"middle_name":"AGNES","last_name":"GERMILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"OSUNA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145183,"prefix":null,"prefix_display":null,"first_name":"ZOE","nickname":null,"middle_name":null,"last_name":"SALZBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152388,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"WING","last_name":"HARPER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/4150fb21-6764-4629-a6d9-ed58dd4a4200/","filing_uuid":"4150fb21-6764-4629-a6d9-ed58dd4a4200","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/4150fb21-6764-4629-a6d9-ed58dd4a4200/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-07-17T10:20:36-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, and beneficiary protections.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with \"\"Parkinson's disease or a similar movement disorder\"\", and specifically elect to participate in such classes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/4150fb21-6764-4629-a6d9-ed58dd4a4200/","filing_uuid":"4150fb21-6764-4629-a6d9-ed58dd4a4200","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/4150fb21-6764-4629-a6d9-ed58dd4a4200/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-07-17T10:20:36-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, and beneficiary protections.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with \"\"Parkinson's disease or a similar movement disorder\"\", and specifically elect to participate in such classes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. H.Amdt.196: An amendment to the 2026 Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026) that removed three pesticide-related provisions. The amendment eliminated language that would have: (1) limited certain lawsuits against pesticide manufacturers by making it more difficult to bring failure-to-warn claims based on health risks not included on EPA-approved labels; (2) restricted state and local governments from adopting pesticide requirements that exceed federal standards; and (3) modified environmental permitting and oversight requirements for pesticide use, including provisions affecting implementation of the Clean Water Act and other environmental laws.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/24ba8cd0-b72a-4814-b503-fc90d7fb611e/","filing_uuid":"24ba8cd0-b72a-4814-b503-fc90d7fb611e","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/24ba8cd0-b72a-4814-b503-fc90d7fb611e/print/","filing_document_content_type":"text/html","income":null,"expenses":"300000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Sarai King","dt_posted":"2026-07-20T10:28:04-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1800 Massachusetts Avenue, NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":34887,"url":"https://lda.gov/api/v1/registrants/34887/","house_registrant_id":30810,"name":"SERVICE EMPLOYEES INTERNATIONAL UNION CTW-CLC","description":"Labor Union","address_1":"1800 Massachusetts Avenue, NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20036","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SARAI KING","contact_telephone":"+1 202-730-7000","dt_updated":"2026-07-29T10:19:26.383952-04:00"},"client":{"id":143096,"url":"https://lda.gov/api/v1/clients/143096/","client_id":12,"name":"SERVICE EMPLOYEES INTERNATIONAL UNION CTW-CLC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-10-03"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Meetings with Rep. Doggett Office and Minority Staff of the Senate Finance Committee to discuss legislation in support of Biden era CMS Nursing Home Staffing Rule (i.e., H.R. 810, Safe Staffing Saves Lives Act and S. 3866, Nurses Belong in Nursing Homes Act), and continued opposition to Administrative and Congressional efforts to weaken or eliminate Biden era nursing home minimum staffing rule. Meeting with Minority staff of Senate Finance Committee, House Budget Committee, House Education and Workforce, and Energy and Commerce to learn more about HHS Secretary budget hearing featuring Sec. Kennedy. Meeting with minority staff of Senate Finance Committee and several Senate offices to discuss their long term care (LTC) vision document and efforts to reform LTC.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71848,"prefix":null,"prefix_display":null,"first_name":"ISAIAH","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144292,"prefix":null,"prefix_display":null,"first_name":"DALEN","nickname":null,"middle_name":null,"last_name":"HARRIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66443,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"SCOTT","last_name":"GRAY","suffix":"iii","suffix_display":"III"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Meetings, letters, briefings and recommendations to the entire House and Senate after passage of Budget Reconciliation (i.e., H. Con Res. 14, S. Con Res. 7, H.R. 1) and discussions on implementation and further legislation to curb cuts/changes to Medicaid authorized after passage of bill. Meetings with Members of Congress in both the House and Senate in support of legislation to extend ACA Tax Credits after discharge petition (i.e., H.R. 780, 5145, 247; S. 46) and repeal cuts in H.R. 1 (H.R. 4849, S. 2556). Meeting with House Budget Committee staff, Leader Jeffries office, Sen. Schumer Office, Senate HELP staff, Ways and Means staff, Energy and Commerce Staff, and Senate Finance Staff in opposition to Reconciliation 2.0 and any additional health care cuts as offsets to fund ICE and CBP. L-HHS 2027 Appropriations.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138837,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":"DAVID","last_name":"HEYDEMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71848,"prefix":null,"prefix_display":null,"first_name":"ISAIAH","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144292,"prefix":null,"prefix_display":null,"first_name":"DALEN","nickname":null,"middle_name":null,"last_name":"HARRIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66443,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"SCOTT","last_name":"GRAY","suffix":"iii","suffix_display":"III"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Advocating for labor policy changes including raising the federal minimum wage and expanding rights for workers to join a union and enter into CBAs with their employers. S 1332, HR 2743, Raise the Wage Act; S1352, HR 2736, Public Service Freedom to Negotiate Act; S 852, HR 20- Richard L. Trumka Protecting the Right to Organize Act of 2025. Consultation and meetings with Rep. Alexandria Ocasio-Cortez legislative staff and Senator Patty Murray Office on introduction of legislation to rescind DOLs proposed rule related to Fair Labor Standards Act (FLSA) for domestic service employees (i.e., H.R. 7917, Fair Wages for Home Care Workers Act). Meeting with minority staff of House Education and Workforce Committee Staff to discuss and learn more about Bad Medicine: Politics, Unions and Antisemitism in Health Care hearing. Meeting with minority staff of House Education and Workforce Committee Staff to discuss temporary staffing in healthcare and SEIU position. Discussion of Jobs Guarantee Resolution with Pressley team (No Bill Number), H.R. 8555 and Senate companion, H.R. 9571.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138837,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":"DAVID","last_name":"HEYDEMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":144292,"prefix":null,"prefix_display":null,"first_name":"DALEN","nickname":null,"middle_name":null,"last_name":"HARRIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71848,"prefix":null,"prefix_display":null,"first_name":"ISAIAH","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Meetings with minority staff of House Ways and Means in opposition to H.R. 2199/S. 4750, the Restore Protections for Dialysis Patients Act. Consultation with staff of Rep. Debbie Dingell, and supported introduction of H.R. 5228, HCBS Workers Protection Act of 2025 and revisions as they draft HCBS Access Act in 119th Congress. SEIU also worked closely with Congresswomans office on press conference as she reintroduced these bills on April 29, 2026. Meeting with Senate HELP Committee to talk about Large Dialysis Providers duopoly and learn more about Senate oversight of this industry. Meeting with House and Senate Democratic Offices, minority staff of House Budget Committee, Ways and Means Committee, minority staff of House Energy and Commerce Committee, and minority staff of Senate Finance to discuss GOP Waste, Fraud and Abuse Narrative to scale back Medicaid and childcare dollars. Meeting with Rep. Schakowsky office in support of reintroducing Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act. Meeting with Kassandra Navarro (Sen. Blumenthal) and email to Mike Dunn (Rep. Larson) to discuss SEIU position on any revisions to Essential Caregivers Act (S. 3492/H.R. 6766). Prepped SEIU Members and supported Congressional Progressive Caucus (CPC) Shadow Hearing on lowering healthcare costs. Meeting with Rep. Simon aide to discuss SEIU healthcare and childcare priorities.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144292,"prefix":null,"prefix_display":null,"first_name":"DALEN","nickname":null,"middle_name":null,"last_name":"HARRIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"IMM","general_issue_code_display":"Immigration","description":"Path to Legal Status - S. 2468, H.R. 4698, H.R. 1589 Temporary Protected Status - H.R. 1689, S. 4814 Temporary and work visas - bills in formation Appropriations and reconciliation - S.2 Immigration Reform - H.R. 4638 and H.R. 1958","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66443,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"SCOTT","last_name":"GRAY","suffix":"iii","suffix_display":"III"},"covered_position":null,"new":false},{"lobbyist":{"id":51234,"prefix":null,"prefix_display":null,"first_name":"JOSH","nickname":null,"middle_name":null,"last_name":"BERNSTEIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CIV","general_issue_code_display":"Civil Rights/Civil Liberties","description":"Advocating for democracy reforms that make elections more transparent, get more people involved in the political process, and expand voting rights. John R. Lewis Voting Rights Advancement Act of 2025. Advocating against laws that would make it harder for eligible voters to register and participate in elections. HR 22, S 128- Safeguard American Voter Eligibility (SAVE) Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71848,"prefix":null,"prefix_display":null,"first_name":"ISAIAH","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66443,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"SCOTT","last_name":"GRAY","suffix":"iii","suffix_display":"III"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRA","general_issue_code_display":"Transportation","description":"Advocating for service workers within both the aviation/airports and other transportation sectors. The Good Jobs for Good Airports Act- will be reintroduced in July.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71848,"prefix":null,"prefix_display":null,"first_name":"ISAIAH","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CSP","general_issue_code_display":"Consumer Issues/Safety/Products","description":"Meeting with majority and minority staff of Senate HELP Committee to discuss Patients Deserve Price Tag Act, AI legislation and price transparency bills. Meeting with Senator Murphys staff to discuss SEIU support for legislation that would limit private equity and REIT control of hospitals and skilled nursing facilities. Meeting with minority staff of House Oversight Committee in opposition to Stopping Fraudulent Payments Act (H.R. 8464) and Fraud Prevention and Accountability Act (H.R. 8312). We also raised alarms with staff about Pre Payment Fraud Prevention and Treasury Data Access Act (H.R 8463) and Timely and Accurate Benefits Act of 2025 (H.R. 1755). We also sent a letter widely to all House Members to alert them to oppose H.R. 8464 and H.R. 8312, and for further congressional scrutiny of H.R. 8463 and H.R. 1755.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144292,"prefix":null,"prefix_display":null,"first_name":"DALEN","nickname":null,"middle_name":null,"last_name":"HARRIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"The Farm, Food, and National Security Act of 2026 (H.R. 7567) - Lobbied against the passage of this bill. Addressed the negative impact this bill will have on merit staffers and the concern for the exclusion of SNAP language in this bill. Agricultural Act of 2026 (or Farm Bill 2.0) - Lobbied in the Senate against the passage of this bill. Addressed the negative impact this bill will have on merit staffers and the concern for the exclusion of SNAP language in this bill.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":148318,"prefix":null,"prefix_display":null,"first_name":"ALISA","nickname":null,"middle_name":null,"last_name":"FARLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"No Aid for Ghost Students Act of 2026 - H.R. 7892 - Lobbied against this bill. Addressed the impact it will have on students and families pursuing higher education.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":148318,"prefix":null,"prefix_display":null,"first_name":"ALISA","nickname":null,"middle_name":null,"last_name":"FARLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"BAN","general_issue_code_display":"Banking","description":"Opposed HR 3633 the Clarity Act that sets up a weak regulatory scheme for crypto currency.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66443,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"SCOTT","last_name":"GRAY","suffix":"iii","suffix_display":"III"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"FAM","general_issue_code_display":"Family issues/Abortion/Adoption","description":"Stop Child Care Scams Act of 2026 - H.R. 7726 - Lobbied against the passage of this bill and the negative impact it will have on families and childcare providers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":148318,"prefix":null,"prefix_display":null,"first_name":"ALISA","nickname":null,"middle_name":null,"last_name":"FARLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"INS","general_issue_code_display":"Insurance","description":"Meeting with Minority staff of Senate Finance Committee and several Senate offices to discuss private insurance reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144292,"prefix":null,"prefix_display":null,"first_name":"DALEN","nickname":null,"middle_name":null,"last_name":"HARRIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"Misc. AI-related bill drafts (no bill numbers yet).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138837,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":"DAVID","last_name":"HEYDEMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Opposed S.4744/HR9237 that reorganized the VA.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66443,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"SCOTT","last_name":"GRAY","suffix":"iii","suffix_display":"III"},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LAW","general_issue_code_display":"Law Enforcement/Crime/Criminal Justice","description":"Advocating against legislation that would dilute the judiciary and the powers granted to the branch by Article 3 of the Constitution and case law precedent. HR 1702- the Judicial Understaffing Delays Getting Emergencies Solved (JUDGES) Act HR 1789- the Promptly Ending Political Prosecutions and Executive Retaliation (PEPPER) Act HR 1526 - No Rogue Rulings Act (NORRA)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71848,"prefix":null,"prefix_display":null,"first_name":"ISAIAH","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/82d0e925-8f96-4e10-bb9b-ced64071378f/","filing_uuid":"82d0e925-8f96-4e10-bb9b-ced64071378f","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/82d0e925-8f96-4e10-bb9b-ced64071378f/print/","filing_document_content_type":"text/html","income":null,"expenses":"1800000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Robert Egge","dt_posted":"2026-07-20T12:42:58-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"655 15th Street, NW","registrant_address_2":"Suite 500","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":1262,"url":"https://lda.gov/api/v1/registrants/1262/","house_registrant_id":30526,"name":"ALZHEIMER'S ASSOCIATION","description":null,"address_1":"655 15th Street, NW","address_2":"Suite 500","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ROBERT EGGE","contact_telephone":"+1 202-638-8660","dt_updated":"2026-07-30T10:03:36.870640-04:00"},"client":{"id":102599,"url":"https://lda.gov/api/v1/clients/102599/","client_id":12,"name":"ALZHEIMER'S ASSOCIATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-10"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"NAPA Reauthorization Act (P.L. 118-92) Alzheimers Accountability and Investment Act (P.L. 118-93) Comprehensive Care for Alzheimers Act (S. 626/H.R. 1637 118th Congress) Reauthorization of the BOLD Infrastructure for Alzheimer's Act (P.L. 115-406) BOLD Reauthorization Act (P.L. 118-142) Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act (H.R. 3747 / S. 4036) The Senator Elizabeth Dole 21st Century Veterans Healthcare and Benefits Improvement Act (P.L. 118-210) VA Clinician Appreciation, Recruitment, Education, Expansion, and Retention Support (CAREERS) Act of 2023 (S. 10 118th Congress) Access to Innovative Treatments Act of 2026 (H.R. 9418) Mandating Exclusive Review of Individual Treatments (MERIT) Act of 2023 (H.R. 133 118th Congress) Elder Justice Reauthorization and Modernization Act of 2026 (H.R. 8060) Expanding Veterans Options for Long-Term Care Act (S. 495/H.R.1815 118th Congress) Palliative Care and Hospice Education and Training Act of 2023 (S. 2287/H.R. 4425) Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2023 (S. 1544/H.R. 1199 118th Congress) Supporting Our Seniors Act (S. 2762) Alleviating Barriers for Caregiving Act (S. 1227/H.R. 2491) Credit for Caring Act (S. 925/H.R. 2036) Lifespan Respite Care Reauthorization Act (S.830/H.R.2560) DeOndra Dixon INCLUDE Project Act of 2025 (H.R. 3491/S. 1838) Paid Family and Medical Leave Tax Credit Extension and Enhancement Act (S. 400/H.R. 996) Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (S. 1261/H.R. 4206) PACE Part D Choice Act (S. 1703/H.R. 3549 118th Congress) Improving Seniors' Access to Timely Care Act of 2025 (S. 1816/H.R. 3514) Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research and Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779) Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act of 2023(S. 526/H.R. 1092) Essential Caregivers Act (H.R. 6766) Ensuring Patient Access to Critical Breakthrough Products Act (S. 1717/H.R. 5343) The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act (S.2761/H.R.5269) Linking Seniors to Needed Legal Services Act (H.R. 6728) Amending the Rules of the House of Representatives to establish a Permanent Select Committee on Aging (H. Res. 1013) Catching Up Family Caregivers Act of 2026 (S. 4291/H.R. 8273) Improving Retirement Security for Family Caregivers Act of 2026 (S. 4291 /H.R. 8273) Charitable Act (S. 317/H.R. 801) Alzheimers Law Enforcement Education Act of 2025 (H.R. 3389) Health Tech Investment Act (S.1399) One Big Beautiful Bill Act (H.R. 1) Older Americans Act Reauthorization Act of 2025 (S. 2120) Lowering Costs for Caregivers Act of 2025 (S. 1565/H.R. 138) Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act (S. 2761 / H.R. 5269) Enhanced Alerts for Missing Loved Ones with Disabilities Act of 2026 (S. 4670/H.R. 9118) Alzheimers Screening and Prevention Act (H.R. 6130/S. 3267) Other matters related to disaster preparedness and older adults, public health emergencies, public health preparedness and response, telehealth, health disparities, and older Americans/people with disabilities in all phases of emergencies Other matters related to Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Other matters related to care payment models, including the GUIDE model Other matters related to Medicare care planning code 99483 Other matters related to health care workforce shortages Other matters related to home- and community-based services Other matters related to disaster preparedness and older adults Other matters related to Social Security Other matters related to technology-enabled collaborative learning and capacity-building models (Project ECHO) Other matters related to beta-amyloid PET scans Other matters related to selected diagnoses and services rendered under ICD-10 Other matters related to caregiving Other matters related to medical devices Other matters related to rural health Other matters related to veterans' health and traumatic brain injury (TBI) Other matters related to Tricare Other matters related to research Other matters related to biomarkers including blood-based tests and cerebral spinal fluid (CSF) Other matters related to public health Other matters related to elder justice, abuse and neglect Other matters related to Medicaid Other matters related to nonprofit infrastructure and operations Other matters related to the National Plan to Address Alzheimer's Disease and the NAPA Advisory Council Other matters related to the Alzheimer's Screening and Prevention (ASAP) Act Other matters related to the reauthorization of the Alzheimers semipostal stamp Other matters related to brain health, risk reduction, and the U.S. POINTER study and results Other matters related to biomarker disclosure and discrimination (Office of Civil Rights at HHS) Other matters related to long-term care","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55648,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"CONANT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67551,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"POLLACK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140279,"prefix":"ms","prefix_display":"MS.","first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":114396,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"HEATH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141524,"prefix":"mrs","prefix_display":"MRS.","first_name":"MARY","nickname":null,"middle_name":"AGNES","last_name":"GERMILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"OSUNA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145183,"prefix":null,"prefix_display":null,"first_name":"ZOE","nickname":null,"middle_name":null,"last_name":"SALZBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152388,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"WING","last_name":"HARPER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":56,"name":"Federal Emergency Management Agency (FEMA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":5,"name":"Government Accountability Office (GAO)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":138,"name":"Indian Health Service"},{"id":37,"name":"Justice, Dept of (DOJ)"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":91,"name":"Social Security Administration (SSA)"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Matters related to Fiscal Years 2026 and 2027 appropriations for Alzheimers funding at the National Institutes of Health, Centers for Disease Control and Prevention, Food and Drug Administration, Health Resources and Services Administration, Administration for Community Living, Department of Defense, and Indian Health Service Matters related to Fiscal Year 2026 and 2027 appropriations language reflecting scientific advances in Alzheimers at the Food and Drug Administration and the Centers for Medicare & Medicaid Services Appropriations related to OAA Title III-C Nutrition Program and appropriations related to [88 FR 80085] Initiative on Women's Health Research Other matters related to Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease Other matters related to beta-amyloid PET scans Other matters related to diagnostics for Alzheimers disease and other dementia Other matters related to brain health and risk reduction Other matters related to clinical trials","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55648,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"CONANT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140279,"prefix":"ms","prefix_display":"MS.","first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67551,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"POLLACK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141524,"prefix":"mrs","prefix_display":"MRS.","first_name":"MARY","nickname":null,"middle_name":"AGNES","last_name":"GERMILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"OSUNA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145183,"prefix":null,"prefix_display":null,"first_name":"ZOE","nickname":null,"middle_name":null,"last_name":"SALZBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152388,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"WING","last_name":"HARPER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[{"name":"ALZHEIMERS IMPACT MOVEMENT (AIM)","url":"https://alzimpact.org","address_1":"655 15th Street, NW, Ste. 500","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_city":null,"ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America"}]},{"url":"https://lda.gov/api/v1/filings/d0713f03-58a0-4530-af86-49449d2e71bc/","filing_uuid":"d0713f03-58a0-4530-af86-49449d2e71bc","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/d0713f03-58a0-4530-af86-49449d2e71bc/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-10-19T10:17:06-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, and beneficiary protections.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with \"\"Parkinson's disease or a similar movement disorder\"\", and specifically elect to participate in such classes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Opposition to OMB-2026-0034, Regulation for Federal Financial Assistance, which would make broad changes to the Uniform Guidance governing federal grants and cooperative agreements across federal agencies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d0713f03-58a0-4530-af86-49449d2e71bc/","filing_uuid":"d0713f03-58a0-4530-af86-49449d2e71bc","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/d0713f03-58a0-4530-af86-49449d2e71bc/print/","filing_document_content_type":"text/html","income":null,"expenses":"150000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael DeRose","dt_posted":"2026-10-19T10:17:06-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Grand Central Station, PO Box 4777","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10163","registrant":{"id":401104060,"url":"https://lda.gov/api/v1/registrants/401104060/","house_registrant_id":null,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","description":"Parkinson's disease research","address_1":"Grand Central Station, PO Box 4777","address_2":null,"address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10163","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL DEROSE","contact_telephone":"+1 212-509-0995","dt_updated":"2026-07-23T15:55:48.243467-04:00"},"client":{"id":200707,"url":"https://lda.gov/api/v1/clients/200707/","client_id":12,"name":"THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project. Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions. Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies. The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions. The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Essential Caregivers Act of 2026 (H.R. 9641), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid. The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias. Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, and beneficiary protections.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2027 appropriations legislation including H.R. 9260 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, H.R. 8469 Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes, H.R. 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027, and other appropriations legislation. Advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA. Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language. Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative. National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers. Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research. Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention. Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias. Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures. Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease. Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio. Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease. Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions. Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications. Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD). Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease. Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures. Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease. The Boxing Therapy for Parkinsons Access Act (H.R. 9150), including advocacy related to requiring the VA to furnish boxing-based exercise classes to veterans who are enrolled in the VA health care system, have been diagnosed with \"\"Parkinson's disease or a similar movement disorder\"\", and specifically elect to participate in such classes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false}],"government_entities":[{"id":25,"name":"Defense, Dept of (DOD)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases. The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":118859,"prefix":null,"prefix_display":null,"first_name":"MASON","nickname":null,"middle_name":null,"last_name":"ZEAGLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care. The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care. The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"The Paraquat Prevention Act (H.R. 9357): This legislation would direct EPA to cancel all registrations for the herbicide paraquat, revoke food-residue tolerances, prohibit the sale and use of existing stocks, and permanently bar re-registration, citing evidence linking paraquat exposure to an increased risk of Parkinsons disease. USDA Environmental Quality Incentives Program (EQIP) to support projects that reduce pesticide use, including paraquat, by prioritizing nonchemical weed-control and crop dry down methods.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false},{"lobbyist":{"id":151815,"prefix":null,"prefix_display":null,"first_name":"GRANT","nickname":null,"middle_name":null,"last_name":"COPE","suffix":null,"suffix_display":null},"covered_position":"Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator","new":false},{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Opposition to OMB-2026-0034, Regulation for Federal Financial Assistance, which would make broad changes to the Uniform Guidance governing federal grants and cooperative agreements across federal agencies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143116,"prefix":null,"prefix_display":null,"first_name":"SALLIE","nickname":null,"middle_name":"JAMES","last_name":"WEART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143739,"prefix":"mr","prefix_display":"MR.","first_name":"DREW","nickname":null,"middle_name":"CHARLES","last_name":"HATTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151814,"prefix":null,"prefix_display":null,"first_name":"DANIELLE","nickname":null,"middle_name":null,"last_name":"MUTONE-SMITH","suffix":null,"suffix_display":null},"covered_position":"USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/ef82bcc8-b23f-411e-b25c-ed9d2899214f/","filing_uuid":"ef82bcc8-b23f-411e-b25c-ed9d2899214f","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/ef82bcc8-b23f-411e-b25c-ed9d2899214f/print/","filing_document_content_type":"text/html","income":null,"expenses":"1400000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Robert Egge","dt_posted":"2026-10-20T11:04:05-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"655 15th Street, NW","registrant_address_2":"Suite 500","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":1262,"url":"https://lda.gov/api/v1/registrants/1262/","house_registrant_id":30526,"name":"ALZHEIMER'S ASSOCIATION","description":null,"address_1":"655 15th Street, NW","address_2":"Suite 500","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ROBERT EGGE","contact_telephone":"+1 202-638-8660","dt_updated":"2026-07-30T10:03:36.870640-04:00"},"client":{"id":102599,"url":"https://lda.gov/api/v1/clients/102599/","client_id":12,"name":"ALZHEIMER'S ASSOCIATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-10"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"NAPA Reauthorization Act (P.L. 118-92) Alzheimers Accountability and Investment Act (P.L. 118-93) Comprehensive Care for Alzheimers Act (S. 626 / H.R. 1637 118th Congress) Reauthorization of the BOLD Infrastructure for Alzheimer's Act (P.L. 115-406) BOLD Reauthorization Act (P.L. 118-142) Accelerating Access to Dementia & Alzheimers Provider Training (AADAPT) Act (H.R. 3747 / S. 4036) The Senator Elizabeth Dole 21st Century Veterans Healthcare and Benefits Improvement Act (P.L. 118-210) VA Clinician Appreciation, Recruitment, Education, Expansion, and Retention Support (CAREERS) Act of 2023 (S. 10 118th Congress) Access to Innovative Treatments Act of 2026 (H.R. 9418) Mandating Exclusive Review of Individual Treatments (MERIT) Act of 2023 (H.R. 133 118th Congress) Elder Justice Reauthorization and Modernization Act of 2023 (S. 1198/H.R. 2718 118th Congress) Expanding Veterans Options for Long-Term Care Act (S. 495/H.R.1815 118th Congress) Palliative Care and Hospice Education and Training Act (S. 2287/H.R. 4425) Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2023 (S. 1544/H.R. 1199 118th Congress) Supporting Our Seniors Act (S. 2762) Alleviating Barriers for Caregiving Act (S. 3109 118th Congress) Credit for Caring Act (S. 925/H.R. 2036) Lifespan Respite Care Reauthorization Act of 2025 (S.830/H.R.2560) DeOndra Dixon Investigation of Co-occurring Conditions across the Lifespan to Understand Down Syndrome (INCLUDE) Project Act of 2026 (H.R. 3491/S. 1838) Paid Family and Medical Leave Tax Credit Extension and Enhancement Act (S. 400/H.R. 996) Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2025 (S. 1261/H.R. 4206) PACE Part D Choice Act (S. 1703/H.R. 3549 118th Congress) Improving Seniors' Access to Timely Care Act of 2025 (S. 1816/H.R. 3514) Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act of 2026 (H.R. 7779) Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act of 2023 (S. 526/H.R. 1092 118th Congress) Essential Caregivers Act of 2025 (H.R. 6766) Ensuring Patient Access to Critical Breakthrough Products Act (S. 1717/H.R. 5343) Linking Seniors to Needed Legal Services Act of 2025 (H.R. 6728) Amending the Rules of the House of Representatives to establish a Permanent Select Committee on Aging (H. Res. 1029 118th Congress) Catching Up Family Caregivers Act (S. 4291 / H.R. 8273) Improving Retirement Security for Family Caregivers Act (S. 4292 / H.R. 8274) Charitable Act (S. 317/H.R. 801) Alzheimers Law Enforcement Education Act (H.R. 3389) Health Tech Investment Act (S.1399) One Big Beautiful Bill Act (H.R. 1) Older Americans Act Reauthorization Act of 2025 (S. 2120) Lowering Costs for Caregivers Act of 2025 (S. 1565 / H.R. 138) Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act (S. 2761 / H.R. 5269) Enhanced Alerts for Missing Loved Ones with Disabilities Act of 2026 (S. 4670 / H.R. 9118) Alzheimers Screening and Prevention Act (H.R. 6130/S. 3267) Other matters related to disaster preparedness and older adults, public health emergencies, public health preparedness and response, telehealth, health disparities, and older Americans/people with disabilities in all phases of emergencies Other matters related to Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Other matters related to care payment models, including the GUIDE model Other matters related to Medicare care planning code 99483 Other matters related to health care workforce shortages Other matters related to home- and community-based services Other matters related to disaster preparedness and older adults Other matters related to Social Security Other matters related to technology-enabled collaborative learning and capacity-building models (Project ECHO) Other matters related to beta-amyloid PET scans Other matters related to selected diagnoses and services rendered under ICD-10 Other matters related to caregiving Other matters related to medical devices Other matters related to rural health Other matters related to veterans' health and traumatic brain injury (TBI) Other matters related to Tricare Other matters related to research Other matters related to biomarkers including blood-based tests and cerebral spinal fluid (CSF) Other matters related to public health Other matters related to elder justice, abuse and neglect Other matters related to Medicaid Other matters related to nonprofit infrastructure and operations Other matters related to the National Plan to Address Alzheimer's Disease and the NAPA Advisory Council Other matters related to the Alzheimer's Screening and Prevention (ASAP) Act Other matters related to the reauthorization of the Alzheimers semipostal stamp Other matters related to brain health, risk reduction, and the U.S. POINTER study and results Other matters related to biomarker disclosure and discrimination (Office of Civil Rights at HHS) Other matters related to long-term care Other matters related to drug development","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55648,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"CONANT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67551,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"POLLACK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140279,"prefix":"ms","prefix_display":"MS.","first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":114396,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"HEATH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141524,"prefix":"mrs","prefix_display":"MRS.","first_name":"MARY","nickname":null,"middle_name":"AGNES","last_name":"GERMILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"OSUNA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145183,"prefix":null,"prefix_display":null,"first_name":"ZOE","nickname":null,"middle_name":null,"last_name":"SALZBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152388,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"WING","last_name":"HARPER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":134,"name":"Centers For Disease Control & Prevention (CDC)"},{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":56,"name":"Federal Emergency Management Agency (FEMA)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":5,"name":"Government Accountability Office (GAO)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":138,"name":"Indian Health Service"},{"id":37,"name":"Justice, Dept of (DOJ)"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":91,"name":"Social Security Administration (SSA)"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Matters related to Fiscal Years 2026 and 2027 appropriations for Alzheimers funding at the National Institutes of Health, Centers for Disease Control and Prevention, Food and Drug Administration, Health Resources and Services Administration, Administration for Community Living, Department of Defense, and Indian Health Service Matters related to Fiscal Year 2026 and 2027 appropriations language reflecting scientific advances in Alzheimers at the Food and Drug Administration and the Centers for Medicare & Medicaid Services Appropriations related to OAA Title III-C Nutrition Program and appropriations related to [88 FR 80085] Initiative on Women's Health Research Other matters related to Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease Other matters related to beta-amyloid PET scans Other matters related to diagnostics for Alzheimers disease and other dementia Other matters related to brain health and risk reduction Other matters related to clinical trials","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55648,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"CONANT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140279,"prefix":"ms","prefix_display":"MS.","first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67551,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"POLLACK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141524,"prefix":"mrs","prefix_display":"MRS.","first_name":"MARY","nickname":null,"middle_name":"AGNES","last_name":"GERMILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145182,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"OSUNA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145183,"prefix":null,"prefix_display":null,"first_name":"ZOE","nickname":null,"middle_name":null,"last_name":"SALZBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152388,"prefix":"ms","prefix_display":"MS.","first_name":"JENNIFER","nickname":null,"middle_name":"WING","last_name":"HARPER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}